Last updated on August 2019

Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)


Brief description of study

To determine the long-term nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with primary and genetic focal segmental glomerulosclerosis (FSGS).

Detailed Study Description

This is a randomized, multicenter, double-blind, parallel, active-control study. Approximately 300 patients aged 8 to 75 years (inclusive) will be enrolled in the study. The study will be conducted in approximately 240 study centers, globally. The investigational drug (sparsentan) is a dual-acting angiotensin receptor blocker and endothelin receptor antagonist. The active control is irbesartan. Patients who meet eligibility criteria will require washout from renin-angiotensin-aldosterone system (RAAS) blockers, if applicable prior to their first dose of study drug.

Patients will be randomly assigned in a 1:1 ratio to receive either sparsentan or active control (irbesartan).

Clinical Study Identifier: NCT03493685

Find a site near you

Start Over

Retrophin Investigational Site

Concord, Australia
1.38miles
  Connect »

Retrophin Investigational Site

St. Leonards, Australia
4.77miles
  Connect »